McKesson Corporation

McKesson's RSI of 29.4 signals oversold territory—a rare occurrence for a $106B defensive healthcare stalwart. Trading at a 23x P/E multiple typical of its sector, the stock appears fairly valued despite the depressed momentum indicator, suggesting the recent pullback stems from broader market weakness rather than fundamental deterioration. With only 2.11% short interest, there's minimal squeeze potential, but the oversold RSI presents a classic mean-reversion setup for those comfortable with the pharmaceutical distribution narrative. The absence of extreme valuation compression makes this less of a bargain hunt and more of a patience play awaiting technical stabilization.